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Abstract
Introduction: Inflammation, the key regulator of C-reactive protein (CRP) synthesis, plays a pivotal role in
atherothrombotic cardiovascular disease.
Methods: High sensitivity CRP (hsCRP) analysis was carried out in randomly selected 600 individuals from the
sentinel surveillance study in Indian industrial population (SSIP). The hsCRP was measured quantitatively by turbid
metric test using kits from SPINREACT, Spain. We analyzed the association between hsCRP and traditional CVD risk
factors in this sub-sample.
Results: Complete risk factor data and CRP levels were available from 581/600 individuals. One half (51.2%) of the
study subjects were males. Mean age of the study group was 39.2 ± 11.2 years. The Pearson correlation coefficients
were in the range of 0.12 for SBP (p = 0.004) to 0.55 for BMI (p < 0.001). The linear regression coefficients ranged
from 0.01 for SBP, PG and TC (p < 0.001) to 0.55 for logeTAG (p < 0.001) after adjustment for age, sex and
education. The mean of logehsCRP significantly increased (P < 0.001) from individuals with ≤1 risk factors (-0.50) to
individuals with three or more risk factors (0.60). In the multivariate model, the odds ratios for elevated CRP (CRP ≥
2.6 mg/dl) were significantly elevated only in females in comparison to males (1.63, 95% CI; 1.02-2.58), overweight
individuals in comparison to normal weight individuals (3.90, 95% CI; 2.34-6.44, p < 0.001), and abdominal obese
individuals (1.62, 95% CI; 1.02-2.60, p = 0.04) in comparison to non-obese individuals.
Conclusion: Clinical measurements of adiposity (body mass index and abdominal obesity) correlate well and can
be surrogate for systemic inflammatory state of individuals.
Introduction
While more than two third of all reported deaths are attri-
butable to non-communicable diseases in India, close to
one third of all deaths are due to cardiovascular disease
(CVD) alone [1,2]. As the overall burden of CVD con-
tinues to grow, it is expected to be the leading cause of
death and disability by 2020 (2). Excess risk of CVD
among individuals from the Indian sub-continent, despite
lower or similar levels of traditional risk factors have been
documented among migrants from the Indian subconti-
nent, in comparison to the non-migrant host country
populations [3]. Numerous novel biomarkers have been
proposed to have mechanistically plausible links to clinical
CVD and their risk factors, with many reported to identify
people at an increased risk for future cardiovascular events
independent of the presence of established risk factors [4].
However, the strength of the dose response relationship of
these novel risk factors with cardiovascular events and
their role in risk stratification and risk prediction need to
be established more precisely [4,5].
Role of inflammation in the pathogenesis of athero-
sclerosis especially the associations between C-reactive
protein (CRP), a plasma protein synthesized in liver,
with cardiovascular risk factors and disease risk have
gained much attention in the recent past [6]. CRP is a
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tors of the inflammatory cascade (e.g., interleukin 6).
While CRP is elevated in a variety of conditions, a link
has been suggested between CRP and pathogenesis of
clinical cardiovascular disease. For example, a recent
meta-analysis of 54 long-term prospective studies sug-
gests continuous association of CRP with risk of coronary
heart disease (CHD), ischemic heart disease (IHD), and
vascular mortality independent of conventional risk fac-
tors [7]. Anand and Yusuf recently analyzed the collective
evidence of causal association between CRP and CVD
and suggested CRP as a bystander (marker) of CVD
rather than a causal factor [8]. However, research on
association between CRP and cardiovascular risk factors
and diseases may be more relevant among Indians who
are at a significantly higher risk of developing insulin
resistance, diabetes mellitus and CHD [9]. The relation-
ships between CRP levels and conventional risk factors of
CVD in the Indian population are described in this paper.
Methods
Study design and population
We carried out hsCRP analysis in 4 out of 10 industrial
sites from the sentinel surveillance study in Indian indus-
trial population (SSIP) chosen to represent the North
(Delhi), South (Trivandrum), West (Nagpur) and East
(Dibrugarh) regions of the country. The details of the SSIP
have been described previously [10,11]. In brief, ten indus-
trial sites across India participated in the study. All employ-
ees and their family members between the ages of 20 and
69 years were eligible to be included in the study. Risk fac-
tor data were obtained from randomly selected employees
and their eligible family members (n = 9600 from four
sites). From this group, we chose 6000 individuals by strati-
fied random sub-sampling for blood lipids and fasting
blood glucose analysis. Further, we randomly chose 600
individuals for serum hsCRP estimation from this group.
The sample selection method is illustrated in Figure 1.
Demographic details and lifestyle habits were obtained
using a structured questionnaire. The anthropometric pro-
file was measured using standard procedures and equip-
ments. Blood pressure was measured using automated BP
monitoring equipment (Omron MX3). Two measure-
ments were taken at least 5 minutes apart and before col-
lecting the blood samples. Study subjects were instructed
in advance not to consume any drinks and tobacco at least
one hour before attending the screening clinic.
Laboratory analysis
A minimum 8-hour fasting blood sample was collected
for biochemical analysis of blood glucose, lipids and
hsCRP. Biochemical assays were performed at the
Department of Cardiac Biochemistry at All India Institute
of Medical Sciences (AIIMS), New Delhi. Details of
biochemical analysis and quality control measures are
published elsewhere [10]. Briefly, glucose was analyzed by
means of glucose oxidase method (GOD-PAP, Randox).
Cholesterol estimation was by CHOD-PAP and triglycer-
ides by GPO-PAP method (Randox). HDL was estimated
by the precipitation method using phosphotungstate/
MgCl2. The method entails precipitation of Apo B con-
taining lipoproteins followed by estimation of cholesterol
in the supernatant by enzymatic method.
T h eh s C R Pw a sm e a s u r e dq u a n t i t a t i v e l yb yt u r b i d
metric test using kits from SPINREACT, Spain. Latex
particles coated with specific anti-human CRP were
agglutinated when mixed with samples containing CRP.
The agglutination causes an absorbance change depend-
ing upon the CRP content in the sample. The absor-
bance change was quantified using calibrators of known
CRP concentration (calibration curve). The linearity of
the method was up to 10 mg/l. All the samples having
values >10 mg/l were diluted further and reanalyzed.
T h ei n t r a - a s s a yc o e f f i c i e nt of variation was < 5% and
inter-assay coefficient was <10%.
Definitions
Current tobacco use was defined as use of any form of
tobacco products (smoking and smokeless form) in the
SSIP 10 sites: Stratified random sampling 
(N=19973) 
Four sites: Assam, Delhi, Lucknow  and 
Trivandrum (N=9600) 
Biochemical variables: Stratified 
random sub-sampling (N=6000) 
CRP estimation: Random 
sampling (N=600) 
Complete risk factor 
data (N=581) 
Figure 1 Study flow chart. SSIP, sentinel surveillance study in
Indian industrial population.
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index (BMI) ≥ 25 kg/m
2 [12]. Hypertension was defined
as either a systolic blood pressure (SBP) ≥ 140 mmHg,
and/or a diastolic blood pressure (DBP) ≥ 90 mmHg, or
on drug treatment for hypertension [13]. Diabetes was
defined as either a fasting blood glucose value of ≥ 126
mg/dl [14] or on medication for diabetes. Dyslipidemia
was defined as total cholesterol to high-density lipopro-
tein ratio (TC/HDL) of ≥4.5. Hypertriglyceridemia was
defined as triglycerides (TAG) > 150 mg/dl [15]. Ele-
vated hsCRP was defined as hsCRP levels ≥ 75
th percen-
tile (CRP ≥ 2.6 mg/dl).
Statistical analysis
Triglycerides (TAG) and hsCRP data have been trans-
formed using the loge function. Pearson correlation
coefficient was estimated to test the associations of CRP
with other traditional risk factors of CVD (continuous
variables). Linear regression coefficients were estimated
for each CVD risk factors (continuous variables) using
CRP as the dependent variable and after adjustment for
age, sex and education. The standard deviation (SD) and
95% CI of the regression coefficients were estimated.
A regression curve was fitted to demonstrate the asso-
ciation of CRP with each CVD risk factor. Error bars
were used to illustrate the mean difference in CRP levels
(bars representing CI of the mean) according to various
risk factor thresholds. Logistic regression analysis was
performed to calculate both bivariate and multivariate
OR for elevated CRP (CRP ≥ 2 . 6m g / d l ,7 5p e r c e n t i l e
value of CRP in the study population) and their 95% CI.
The data were analyzed by using the Statistical Package
for Social Sciences Version 15 (SPSS, Inc., Chicago, IL).
Results
Characteristics of the study population
Complete risk factor data and CRP levels were available
from 581/600 individuals. One half (51.2%) of the study
subjects were males. Mean age of the study group was
39.2 years (SD = 11.2). Tobacco use was prevalent in
47.2% males and 18.6% females (Table 1). Mean BMI
and waist circumference were 23.0 kg/m
2 (SD = 4.5)
and 80.3 (SD = 12.3) cm. Systolic BP was significantly
higher (p = 0.02) among males (126.6 mmHg, SD =
15.1) in comparison to females (123.6 mmHg, SD =
19.1). Mean diastolic BP was 77.2 (SD = 11.5) mmHg.
Mean TC/HDL-c was significantly elevated (p = 0.04) in
males (4.3, SD = 1.6) in comparison to females (4.0,
SD = 1.6). Similarly, the median triglycerides levels were
significantly higher in males (117.0, IQR = 79.0-164.0)
in comparison to females (89.5, IQR = 66.8-126.0).
While the prevalence of diabetes was 11.8% among
males, it was 6.2% in females (p = 0.02). Prevalence of
hypertension (32.8% Vs 29.3%, p = 0.38) and
dyslipidemia (28.9% Vs 19.0%, p = 0.007) were also sig-
nificantly higher in males in comparison to females. The
median CRP levels were 1.1 (IQR = 0.40-2.10) and 1.2
(IQR = 0.30-3.10) in males and females, respectively.
Association of CRP and CVD risk factors
Body mass index (BMI) in Kg/m
2, waist circumference
(WC) in cm, SBP and DBP in mmHg, plasma glucose
(PG) in mg/dl, total cholesterol (TC) in mg/dl, logetri-
glycerides in mg/dl, and TC/HDL-c were positively cor-
related with logeCRP levels (table 2). The Pearson
correlation coefficients (CC) were in the range of 0.12
for SBP (p = 0.004) to 0.55 for BMI (p < 0.001). The lin-
ear regression coefficients (RC) of all these variables
were positive and statistically significant (table 2 and fig-
ure 2) after adjustment for age, sex and education. The
RC ranged from 0.01 for SBP, PG and TC (p < 0.001) to
0.55 for logeTAG (p < 0.001). HDL-c was negatively cor-
related with logCRP (CC = -0.13, p = 0.002; RC =
-0.015, P = 0.002).
The CRP levels were significantly lower among indivi-
dual with normal blood pressure or pre-hypertension as
compared to individuals with hypertension (p = 0.001),
non-diabetic individuals in comparison to individuals
with diabetes (p < 0.001), normal weight individuals in
comparison to overweight individuals (p < 0.001), physi-
cally active in comparison to sedentary individuals (p <
0.001) and non-dyslipidemic individuals in comparison
to dyslipidemic individuals (p < 0.001) after adjustment
for age and sex (Figure 3). The mean of logehsCRP
Table 1 Characteristics of the study population
Variables Males
N = 305
Females
N = 295
P
value
Age years (mean, SD) 39.8 (11.5) 38.5 (10.8) 0.17
Current tobacco use
(n, %)
144 (47.2) 54 (18.6) <0.001
BMI Kg/m
2 (Mean, SD) 22.5 (3.9) 23.6 (5.1) 0.005
WC cm (Mean, SD) 82.5 (11.7) 77.9 (12.4) <0.001
SBP mmHG (Mean, SD) 126.6 (15.1) 123.6 (19.1) 0.02
DBP mmHG (Mean, SD) 77.9 (10.9) 79.5 (12.0) 0.13
PG mg/dl (Mean, SD) 98.3 (31.4) 95.2 (32.5) 0.24
TC mg/dl (mean, SD) 174.9 (43.8) 174.2 (43.1) 0.85
TAG mg/dl (median, IQR) 117.0
(79.0-164.0)
89.5
(66.8-126.0)
<0.001
HDL-c mg/dl (mean, SD) 43.4 (11.2) 46.3 (11.7) 0.002
TC/HDL-c (mean, SD) 4.3 (1.6) 4.0 (1.6) 0.04
Diabetes (n, %) 36 (11.8) 18 (6.2) 0.02
Hypertension (n, %) 100 (32.8) 85 (29.3) 0.38
Dyslipidemia (n, %) 87 (28.9) 54 (19.0) 0.007
CRP mg/L (median, IQR) 1.1 (0.40-2.10) 1.2 (0.30-3.10) 0.30
BMI, body mass index; WC, waist circumference, SBP, systolic blood pressure;
DBP, Diastolic blood pressure; PG, plasma glucose; TC, total cholesterol; TAG,
triglycerides; HDL-c, high density lipoprotein cholesterol; CRP, c-reactive
protein.
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≤1 risk factors (-0.50) to individuals with three or more
risk factors (0.60) (Figure 4).
In the logistic regression model (table 3) the OR for
elevated hsCRP were significantly higher in females in
comparison to males (1.82, 95% CI; 1.24-2.67), ≥40 years
in comparison to <40 years of age group (1.75, 95% CI;
1.19-2.56), overweight in comparison to normal weight
subjects (6.80, 95% CI; 4.50-10.20), individuals with
abdominal obesity in comparison to individuals with no
abdominal obesity (3.42, 95% CI;2.31-5.07) individuals
with hypertension in comparison to individuals with
normal blood pressure and pre-hypertension (2.07, 95%
CI; 1.40-3.05), diabetic individuals in comparison to
non-diabetic individual (2.34, 95% CI; 1.31-4.18), and
dyslipidemic individuals in comparison to participants
with normal lipid levels (2.04, 95% CI; 1.34-3.09) in the
bivariate model. In the multivariate model, the OR were
significantly elevated only in females in comparison to
males (1.63, 95% CI; 1.02-2.58), overweight individuals
in comparison to normal weight individuals (3.90, 95%
CI; 2.34-6.44, p < 0.001), and abdominal obese indivi-
duals (1.62, 95% CI; 1.02-2.60, p = 0.04) in comparison
to non-obese individuals.
Discussion
We observed significant linear increase in hsCRP levels
with body mass index, waist circumference, systolic and
Table 2 Association between CRP and CVD risk factors
Variables Correlation coefficient (CC, p value) Regression coefficient (RC, 95% CI, p value)*
BMI Kg/m
2 0.55 (<0.001) 0.16 (0.14-0.18, <0.001)
WC cm 0.47 (<0.001) 0.05 (0.04-0.06, <0.001)
SBP mmHG 0.12 (0.004) 0.01 (0.003-0.02, 0.004)
DBP mmHG 0.18 (<0.001) 0.02 (0.01-0.03, <0.001)
PG mg/dl 0.31 (<0.001) 0.01 (0.008-0.014, <0.001)
TC mg/dl 0.32 (<0.001) 0.01 (0.008-0.12, <0.001)
logeTAG mg/dl 0.21 (<0.001) 0.55 (0.34-0.76, <0.001)
HDL-c mg/dl -0.13 (0.002) -0.015 (-0.024 to -0.005, 0.002)
TC/HDL-c 0.28 (<0.001) 0.23 (0.17-0.30, 0.001)
BMI, body mass index; WC, waist circumference; SBP, systolic blood pressure; DBP, Diastolic blood pressure; PG, plasma glucose; TC, total cholesterol; TAG,
triglycerides; HDL-c, high density lipoprotein cholesterol; CRP, c-reactive protein; *Adjusted for age, sex and education.
P<0.001  P<0.001  P<0.001 
P=0.001  P=0.02  P=0.003 
Figure 2 Association between CRP concentration and conventional risk factors of CVD (regression lines). X axis, Loge of CRP; BP, blood
pressure; PG, plasma glucose; TAG, triglycerides.
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and triglycerides after adjustment for age, sex and edu-
cation. There was a linear increase in CRP levels with
increase in mean number of risk factors (0 risk factors
to ≥3 risk factors). However, in the multivariate logistic
model elevated hsCRP was explained by female gender,
overweight and abdominal obesity.
Statistically significant associations of hsCRP with mea-
sures of generalized and regional adiposity were previously
reported in urban Indian males in the age group of 14-25
years [16]. Research data suggests that there is a strong
link between overweight/adiposity with elevated CRP
[17-19]. Our results are consistent with the established
importance of adiposity especially the role of visceral
a d i p o s et i s s u e( V A T )a sas o u r c eo fp r o i n f l a m m a t o r y
cytokines [20]. Obesity increases the production of proin-
flammatory mediators from adipose tissue T cells and con-
tributes to insulin resistance in animal models [21].
Furthermore, low-grade proinflammatory environment
and the insulin resistance associated with obesity may con-
tribute to the down regulation of LPIN1 (a gene with
important effects on metabolic and lipoprotein homeo-
stasis) in adipose tissue, leading to a worse metabolic
profile [22].
hsCRP levels were significantly elevated in individuals
with multiple risk factors of CVD in this population in
comparison to individuals with no risk factors. This
association underscores the likely relationship that well-
established risk factors contribute to the inflammatory
process. However, a causal relationship can not be
P=0.22  P<0.001  P<0.001 
P<0.001  P<0.001  P=0.001 
Figure 3 Association between CRP and risk factors of CVD (error bars). BMI, body mass index; TC/HDL-c, Total cholesterol/High density
lipoprotein cholesterol, hsCRP, high sensitivity C-reactive protein; hsCRP, high sensitivity C-reactive protein.
     
P<0.001  P<0.001  P<0.001 
Figure 4 Association between CRP and physical activity, triglycerides and clustering of risk factors of CVD (error bars). hsCRP, high
sensitivity C-reactive protein.
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sent study. It is highly relevant to further investigate the
association of CRP levels with measures of insulin resis-
tance (overweight, fasting plasma glucose, diabetes,
hypertension and clustering of risk factors) in this popu-
lation. Recent evidence suggests that CRP plays a major
role in the patho-physiologic processes associated with
the metabolic syndrome (a cluster of CVD risk factors).
For example, High levels of CRP have been shown to be
an independent predictor of cardiovascular risk for all
degrees of severity of the metabolic syndrome [23].
Furthermore, several studies demonstrate that CRP can
be used to predict the development of type 2 diabetes
mellitus [24-27]. For example, in the Women’s Health
Study [24], the relative risk of developing diabetes
among women in the highest quartiles of CRP was
Table 3 Association between elevated CRP and CVD risk factors (logistic regression)
Variable Elevated CRP (n, %) Bivariate OR (95% CI, p value) Multivariate OR (95% CI, p value)
Gender
Male 59 (19.0) 1 1
Female 87 (29.9) 1.82 (1.24-2.66, p = 0.002) 1.63 (1.02-2.58, p = 0.04)
Age group
≥40 years 89 (19.2) 1.75 (1.19-2.56, p = 0.004) 1.12 (0.72-1.76, p = 0.61)
<40 years 56 (29.3) 1
Education*
ES1 25 (25.0) 1
ES2 40 (29.0) 1.22 (0.68-2.19, p = 0.45)
ES3 53 (27.7) 1.15 (0.66-2.00, p = 0.61)
ES4 27 (16.2) 0.58 (0.31-1.07, p = 0.08)
Study sites*
Lucknow 48 (29.8) 1
Delhi 43 (27) 0.87 (0.54-1.42, p = 0.58)
Dibrugarh 13 (9.2) 0.24 (0.12-0.64, p < 0.001)
Trivandrum 43 (30.9) 1.05 (0.64-1.72, p = 0.83)
Tobacco use
No 113 (28.4) 1 1
Yes 32 (16.2) 0.50 (0.31-0.75, p = 0.001) 1.04 (0.61-1.77, p = 0.90)
Physical activity*
Sedentary 46 (26.0) 1
Active 49 (19.8) 0.70 (0.44-1.11, p = 0.13)
Overweight
BMI < 25 47 (12.0) 1 1
BMI ≥ 25 98 (48.0) 6.80 (4.5-10.2, P < 0.001) 3.90 (2.34-6.44, p < 0.001)
Abdominal obesity
No 73 (17.3) 1 1
Yes 72 (41.6) 3.42 (2.31-5.07, P < 0.001) 1.62 (1.02-2.60, p = 0.04)
Hypertension
No 82 (20.0) 1 1
Yes 63 (34.1) 2.07 (1.40-3.05, p < 0.001) 1.27 (0.80-2.02, p = 0.31)
Diabetes
No 123 (22.7) 1 1
Yes 22 (40.7) 2.34 (1.31-4.18, p = 0.004) 1.39 (0.71-2.74, p = 0.33)
Dyslipidemia
No 92 (20.7) 1 1
Yes 49 (34.8) 2.04 (1.34-3.09, p = 0.001) 1.45 (0.88-2.37, p = 0.15)
Hypertriglyceredimia*
No 106 (23.5) 1
Yes 37 (26.8) 1.19 (0.77-1.84, p = 0.43)
*Not considered in the multilogistic regression model; CRP, c-reactive protein, OR, Odds ratio; CI, Confidence Interval; BMI, body mass index; ES1, up to primary
level education, ES2, above primary level and up to secondary school education, ES3, above secondary school and up to graduation, ES4, education above
graduation.
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t ow o m e ni nt h el o w e s tq u a r t i l e so fC R P ,e v e na f t e r
adjusting for body mass index, family history of diabetes
mellitus, smoking, and other factors.
To the best of our knowledge this is the first study
from the Indian population living in India showing asso-
ciation with CRP levels and other traditional risk factors
of CVD in the age group of 20-69 years. Our data is
consistent with the large meta-analysis data of 54 pro-
spective studies worldwide (7), and data from adult
migrant Indians in UK [28] and USA [29]. The
increased predisposition of CHD among individuals
from the Indian sub-continent, inability of traditional
risk factors to fully explain the excess CHD risk among
Indians, and relatively high exposure to repeated, persis-
tent and lifelong infections in this population highlights
the importance of studying CRP as a risk marker of
CVD in the Indian population. Prospective studies to
understand the independent relationship of CRP levels
and their interaction with CVD risk factors to cardiovas-
cular endpoints in this population are warranted.
Conclusion
CRP levels and traditional cardiovascular risk factors are
correlated with each other in the Indian population.
Clinical measurements of adiposity (body mass index
and abdominal obesity) readily provide data elucidating
the systemic inflammatory state of individuals.
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